中文

Nurix falls 38% as Sanofi ends a partnered drug program

By · AI-assisted, human-reviewed and edited · · 9 sources · Fact-checked · 3 min read

Why is Nurix Therapeutics stock down today?

Nurix fell 38% after saying Sanofi will stop the early-stage trial of SAR448272, a drug Nurix discovered, and end the program. Nurix no longer expects about $455 million of possible milestones or any royalties from it. Nurix gave no reason; Leerink Partners said Sanofi's investor relations cited nonclinical findings, BioSpace reported. Nurix says its $1.1 billion of cash still lasts into the second half of 2029.

What it means

What changed
Sanofi ended the STAT6 program, so Nurix no longer expects about $455 million of possible milestones, or any royalties, from it.
What hasn't changed
Nurix says its $1.1 billion of cash still lasts into the second half of 2029, and its Phase 3 trial with Roche continues.
Next · By year-end 2026
Kymera expects Phase 2b results for KT-621, a rival oral STAT6 degrader, a test of the target Sanofi was pursuing.
Move
▼ 38.2%
Price
$25.82 → $15.95
Value lost
~$1.1B
Milestones no longer expected
~$455M
Cash, Aug 31
$1.1B
Stated cash runway
Into 2H 2029

Prices: official close, Nasdaq, Nov 4, 2026 · Company data: 10-Q, Aug 31, 2026 · What these numbers mean

Official Nasdaq closes: $15.95 on Nov 4, 2026, against $25.82 on Nov 3. The news came just after the Nov 3 close, so the move runs from it and includes the after-hours fall.

Snapshot at the Nov 4, 2026 close

Enterprise value
$679M†
Price/sales
2.5×
P/E
5.9×
Revenue growth
+739%
Net cash
$1.1B†

Our calculation from the company's filings (latest: 10-Q for the quarter to Aug 31, 2026, filed Oct 13, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Aug 31, 2026. Price $15.95 (official close, Nasdaq); 109.2 million shares (common shares on the cover page of the 10-Q filed Oct 13, 2026). n/m = not meaningful (e.g. negative earnings). † Debt excludes $45.6M of deferred collaboration funding, which the company reports separately.

Nurix lost nearly two-fifths of its market value after its partner Sanofi ended an early-stage drug program, and neither company has publicly explained the decision in full. The drug was not Nurix’s lead program, and Nurix says its cash runway has not changed.

What happened

Sanofi told Nurix it will stop the Phase 1 trial of SAR448272, an oral STAT6 degrader, and end the program, Nurix said just after Tuesday’s close.

  • Nurix closed at $15.95, down 38.2% from the regular-session close of $25.82 before the news (Nasdaq). Using the 109.2 million shares on its latest 10-Q cover, that is about $1.1 billion of market value (our calculation).
  • It was the stock’s largest one-day fall since its 2020 listing; the largest before this was 22.7% in May 2022 (Nasdaq closes, our calculation). The shares had risen 36% this year before the news.
  • In October, Nurix counted itself eligible for about $455 million of future milestones from this program, plus royalties; now it expects none, after earning $10 million when the trial began.
  • Nurix’s chief executive, Arthur Sands, called the news “disappointing” and said Nurix “remains in a strong position”.

What is known about the reason

Nurix’s release gives no reason, and we found no public Sanofi statement. What exists comes second-hand through analysts, and it is partial.

  • Analysts at Leerink Partners said Sanofi’s investor relations cited “emerging nonclinical findings that did not warrant continued development in atopic dermatitis”, BioSpace reported.
  • Analysts at Truist Securities said initial talks pointed to “molecule-specific attributes” rather than a problem with the target, according to BioSpace.
  • Jefferies said Sanofi indicated no immediate patient safety concern and that Nurix’s management had not seen the underlying data, Investing.com reported.
  • Analysts at Oppenheimer said safety signals may have played a part, and also raised data from another Sanofi STAT6 program and a shift in Sanofi’s priorities, according to BioSpace. These are possibilities it raised, not reported facts.

Why the market reacted this way

Sanofi’s decision removes a program Nurix had counted as a source of future payments, in a target that drug makers are pursuing in immunology. By our calculation, the market value lost is more than twice the $455 million of possible milestones, which were never certain. Truist said STAT6 “was not included in our valuation”, BioSpace reported. Jefferies, an investment bank, cut its price target to $36 from $45 and kept a Buy rating, Investing.com reported.

The next test of the target comes from a rival. Kymera expects Phase 2b results for KT-621, its own oral STAT6 degrader, by the end of 2026. Sanofi’s other STAT6 work, with Recludix, is a different kind of drug, an inhibitor rather than a degrader.

What’s coming up for Nurix’s pipeline

Nurix’s latest release gives no dates for its next results. Its chief executive gave two timing goals at a September conference, both for bexobrutideg outside cancer: filing to start trials in chronic spontaneous urticaria, a skin condition, this year, and multiple sclerosis next year.

  • Bexobrutideg, a BTK degrader Nurix develops with Roche, is in a Phase 3 trial against pirtobrutinib in relapsed chronic lymphocytic leukemia (CLL). A separate pivotal Phase 2 trial is designed to support a possible accelerated approval filing.
  • NX-1607, Nurix’s own CBL-B inhibitor, began Phase 1b expansion cohorts in four solid tumor types in September.
  • Gilead continues a Phase 1 trial of the IRAK4 degrader GS-6791 in healthy volunteers.
  • Nurix remains eligible for payments on its other Sanofi programs, which Sanofi may develop further at its discretion.

Does this change Nurix’s future?

Our read: it removes one possible income stream without changing the core of the company, which is bexobrutideg. Nurix had $1.1 billion of cash and marketable securities on Aug 31, after a $700 million upfront payment from Roche, and says that funds it into the second half of 2029. That payment dominates the last 12 months’ results, so the price-to-earnings and price-to-free-cash-flow figures in the snapshot reflect a one-off rather than ongoing profit. It has no approved products, and its 10-Q says it expects to need substantial additional capital to complete development and commercialization.

The other view

Analysts at Truist Securities called the after-hours drop "an overreaction", saying talks pointed to the molecule rather than the target and that STAT6 "was not included in our valuation", BioSpace reported.

Source: BioSpace, Nov 4, 2026

What to watch next

By year-end 2026
Kymera expects Phase 2b results for KT-621, a rival oral STAT6 degrader in atopic dermatitis.
By year-end 2026
Nurix's goal, as its chief executive stated in September, to file to start trials of bexobrutideg in chronic spontaneous urticaria. He said multiple sclerosis would follow next year.
No date given
Bexobrutideg, developed with Roche: Nurix is enrolling a Phase 3 trial and a pivotal Phase 2 trial meant to support a possible accelerated approval filing. Its latest release gives no date for results.
No date given
Nurix's next results, for the fiscal year ending Nov 30: whether it changes its cash runway or says more about Sanofi's decision.

Quick questions

What is a STAT6 degrader?

STAT6 is a protein involved in type 2 inflammation, the process behind conditions such as atopic dermatitis. A degrader is a drug designed to make cells break down a target protein, rather than only block it.

Did Sanofi say why it stopped?

Nurix's release and filing give no reason. BioSpace reported that Leerink Partners heard from Sanofi's investor relations about "emerging nonclinical findings". Investing.com reported that Sanofi indicated no immediate patient safety concern. We have not seen a public Sanofi statement or the data.

About Nurix Therapeutics: Website (external site)Investor relations (external site)SEC filings (external site)

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.